Annals of Surgical Oncology

, Volume 17, Issue 11, pp 3037–3042 | Cite as

Clinical Significance of Human Kallikrein7 Gene Expression in Colorectal Cancer

  • Yasuhiro Inoue
  • Takehiko Yokobori
  • Takeshi Yokoe
  • Yuji Toiyama
  • Chikao Miki
  • Koshi Mimori
  • Masaki Mori
  • Masato Kusunoki
Translational Research and Biomarkers



The human kallikrein-related peptidases (KLK) are considered important prognostic biomarkers in cancer. The aim of the current study is to demonstrate gene expression of KLK7 in colorectal cancer (CRC) and to correlate the relative KLK7 expression level with clinicopathological factors of CRC.


KLK7 messenger RNA (mRNA) expression was examined in nine CRC cancer cell lines by real-time polymerase chain reaction. The expression levels of KLK7 mRNA in cancerous tissues (n = 136) and paired normal tissues (n = 136) of CRC patients were also examined.


Six of the nine cell lines expressed the KLK7 gene. KLK7 mRNA expression levels in cancer tissues were significantly higher than those in normal tissues. Multivariate analysis revealed that the KLK7 mRNA expression level in cancer was an independent prognostic factor, especially in liver metastasis.


We provide evidence suggesting that KLK7 mRNA expression is correlated with prognosis in CRC patients, especially in liver metastasis.


Noncancerous Tissue Paired Normal Tissue KLK7 Expression Cancer Genome Anatomy Project KLK7 mRNA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The funding sources supporting our work are as follows: Grant sponsor: Japan Society for the Promotion of Science (JSPS). Grant-in-Aid for Scientific Research; Grant numbers: 17109013,18659384, 18390367, 18590333, 19591509, 19390336, 20390360, 20591547, 20790961, 20659209, 20790960; Grant sponsor: The Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Grant-in-Aid for Scientific Research on Priority Areas; Grant number: 18015039; Grant sponsor: Third-Term Comprehensive 10-year Strategy for Cancer Control; Grant number: 16271201; Grant sponsors: CREST, Japan Science and Technology Agency (JST); NEDO (New Energy and Industrial Technology Development Organization) Technological Development for Chromosome Analysis; The Ministry of Education, Culture, Sports, Science, and Technology of Japan for Scientific Research on Priority Areas, Cancer Translational Research Project, Japan; Grant of Clinical Research Foundation (2008–2010).


  1. 1.
    Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88(10):2398–424.CrossRefPubMedGoogle Scholar
  2. 2.
    Japan treatment guidelines for colorectal cancer. Japanese Society for Cancer of the Colon and Rectum, editor, Kanehara Co., Tokyo; 2009.Google Scholar
  3. 3.
    Miki C, Inoue Y, Hiro J, Ojima E, Araki T, Uchida K, Kusunoki M. Combined measurement of hepatocyte growth factor and carcinoembryonic antigen as a prognostic marker for patients with dukes a and B colorectal cancer: results of a five-year study. Dis Colon Rectum. 2006;49(11):1710–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review J Natl Cancer Inst. 2007;99(6):433–41.CrossRefPubMedGoogle Scholar
  5. 5.
    André T, Sargent D, Tabernero J, et al. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol. 2006;13(6):887–98.CrossRefPubMedGoogle Scholar
  6. 6.
    Goel A, Arnold CN, Boland CR. Multistep progression of colorectal cancer in the setting of microsatellite instability: new details and novel insights. Gastroenterology. 2001;121(6):1497–502.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhou W, Goodman SN, Galizia G, et al. Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet. 2002;359(9302):219–25.CrossRefPubMedGoogle Scholar
  8. 8.
    Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci. 2004;41(3):265–312.CrossRefPubMedGoogle Scholar
  9. 9.
    Yousef GM, Chang A, Scorilas A, Diamandis EP. Genomic organization of the human kallikrein gene family on chromosome 19q13.3-q13.4. Biochem Biophys Res Commun. 2000;276(1):125–33.CrossRefPubMedGoogle Scholar
  10. 10.
    Borgoño CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer. 2004;4(11):876–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53(8):1423–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Emami N, Diamandis EP. Utility of kallikrein-related peptidases (KLKs) as cancer biomarkers. Clin Chem. 2008;54(10):1600–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Lundström A, Egelrud T. Stratum corneum chymotryptic enzyme: a proteinase which may be generally present in the stratum corneum and with a possible involvement in desquamation. Acta Derm Venereol. 1991;71(6):471–4.PubMedGoogle Scholar
  14. 14.
    Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, Diamandis EP. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem. 2003;36(2):135–43.CrossRefPubMedGoogle Scholar
  15. 15.
    Dong Y, Kaushal A, Brattsand M, Nicklin J, Clements JA. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res. 2003;9(5):1710–20.PubMedGoogle Scholar
  16. 16.
    Talieri M, Diamandis EP, Gourgiotis D, Mathioudaki K, Scorilas A. Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb Haemost. 2004;91(1):180–6.PubMedGoogle Scholar
  17. 17.
    Talieri M, Li L, Zheng Y, et al. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br J Cancer. 2009;100(10):1659–65.CrossRefPubMedGoogle Scholar
  18. 18.
    Talieri M, Mathioudaki K, Prezas P, et al. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost. 2009;101(4):741–7.PubMedGoogle Scholar
  19. 19.
    Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002;62(13):3819–25.PubMedGoogle Scholar
  20. 20.
    Ogawa K, Utsunomiya T, Mimori K, et al. Genomic screens for genes upregulated by demethylation in colorectal cancer: possible usefulness for clinical application. Int J Oncol. 2005;27(2):417–26.PubMedGoogle Scholar
  21. 21.
    Debela M, Magdolen V, Schechter N, et al. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem. 2006;281(35):25678–88.CrossRefPubMedGoogle Scholar
  22. 22.
    Debela M, Goettig P, Magdolen V, Huber R, Schechter NM, Bode W. Structural basis of the zinc inhibition of human tissue kallikrein 5. J Mol Biol. 2007;373(4):1017–31.CrossRefPubMedGoogle Scholar
  23. 23.
    Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Järvinen H, Haglund C. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology. 2004;66(4):296–302.CrossRefPubMedGoogle Scholar
  24. 24.
    Duffy MJ, van Dalen A, Haglund C, et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43(9):1348–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Yousef GM, Borgoño CA, Popalis C, Yacoub GM, Polymeris ME, Soosaipillai A, et al. In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. Anticancer Res. 2004;24(1):43–51.PubMedGoogle Scholar
  26. 26.
    Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 2007;249(1):61–79.CrossRefPubMedGoogle Scholar
  27. 27.
    Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, Ignatenko NA. Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells. Neoplasia. 2008;10(2):140–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Caubet C, Jonca N, Brattsand M, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol. 2004;122(5):1235–44.CrossRefPubMedGoogle Scholar
  29. 29.
    Michael IP, Kurlender L, Memari N, et al. Intron retention: a common splicing event within the human kallikrein gene family. Clin Chem. 2005;51(3):506–15.CrossRefPubMedGoogle Scholar
  30. 30.
    Brattsand M, Stefansson K, Lundh C, Haasum Y, Egelrud T. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol. 2005;124(1):198–203.CrossRefPubMedGoogle Scholar
  31. 31.
    Yousef GM, Scorilas A, Magklara A, Soosaipillai A, Diamandis EP. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family - genomic characterization, mapping, tissue expression and hormonal regulation. Gene. 2000;254(1–2):119–28.CrossRefPubMedGoogle Scholar
  32. 32.
    Planque C, de Monte M, Guyetant S, et al. KLK5 and KLK7, two members of the human tissue kallikrein family, are differentially expressed in lung cancer. Biochem Biophys Res Commun. 2005;329(4):1260–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Tanimoto H, Underwood LJ, Shigemasa K, Yan Yan MS, Clarke J, Parmley TH, O’Brien TJ. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer. 1999;86(10):2074–82.CrossRefPubMedGoogle Scholar
  34. 34.
    Santin AD, Cane’ S, Bellone S, et al. The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells. Gynecol Oncol. 2004;94(2):283–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, Diamandis EP. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem. 2003;36(2):135–43.CrossRefPubMedGoogle Scholar
  36. 36.
    Bissell MJ, Kenny PA, Radisky DC. Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol. 2005;70:343–56.CrossRefPubMedGoogle Scholar
  37. 37.
    Lundström A, Egelrud T. Cell shedding from human plantar skin in vitro: evidence that two different types of protein structures are degraded by a chymotrypsin-like enzyme. Arch Dermatol Res. 1990;282(4):234–7.CrossRefPubMedGoogle Scholar
  38. 38.
    Johnson SK, Ramani VC, Hennings L, Haun RS. Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer. 2007;109(9):1811–20.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • Yasuhiro Inoue
    • 1
  • Takehiko Yokobori
    • 2
  • Takeshi Yokoe
    • 1
  • Yuji Toiyama
    • 1
  • Chikao Miki
    • 1
  • Koshi Mimori
    • 2
  • Masaki Mori
    • 3
  • Masato Kusunoki
    • 1
  1. 1.Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life SciencesMie University Graduate School of MedicineTsu, MieJapan
  2. 2.Department of Surgical Oncology, Medical Institute of BioregulationKyushu UniversityKyushuJapan
  3. 3.Department of SurgeryOsaka University Graduate School of MedicineOsakaJapan

Personalised recommendations